FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate
- Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals
- Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development
Heidelberg, Germany – 2 June 2026 – FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate receptor (NMDAR) modulators aimed at delivering rapid and sustained relief for patients with treatment-resistant depression (TRD), today announces the appointment of Dr. Hans Eriksson as Chief Medical Officer.
